UTHR
Another big insider sale
United Therapeutics got a fresh dose of “hmm, interesting” after CFO James Edgemond sold 10,000 shares on April 16 at an average price of $577.18, pocketing about $5.77 million. After the trade, he still held 18,876 shares, but that’s a 34.63% trim from his stake.
The plot thickens
This wasn’t a one-off panic button. According to the filing, Edgemond had already been making similar 10,000-share sales through March and April, which makes this look less like a random day-trade and more like a steady drip out the door.
Not just the CFO
He’s not alone either. The article says CEO Martine Rothblatt sold roughly 9,500 shares, worth about $5.5 million, and EVP Paul A. Mahon sold 8,300 shares for about $4.79 million. When the exec suite starts heading for the exit with the same moving boxes, investors usually notice.
Why you should care
Insider selling doesn’t automatically mean trouble — executives sell for plenty of boring reasons, like taxes or diversification. But when multiple senior leaders are unloading meaningful chunks at the same time, it can hang over sentiment and make the market wonder whether the stock is looking a little too comfy around current levels.
Big picture: this is the kind of filing that won’t rewrite the business, but it can absolutely tweak the mood music around the stock.